Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Alexios Matikas(Karolinska University Hospital), Theodoros Foukakis(Karolinska Institutet), Tobias Lekberg(Karolinska University Hospital), Tullia Lindsten(The Wistar Institute), John Lövrot(Karolinska University Hospital), Ann Erlandsson(Örebro University), Anna Ramberg(Karlstad Central Hospital), Jonas Bergh(Karolinska Institutet), Mia Eriksson(Karlstad Central Hospital), Thomas Hatschek(Karolinska University Hospital), Niklas Loman(Lund University), Ingrid Hedenfalk(Lund University)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k